ライフサイエンスコーパス: respiratory tract infection

1 for Haemophilus colonization and subsequent respiratory tract infection.

2 ial virus (HRSV) is a major cause of serious respiratory tract infection.

3 edia occurs as a complication of viral upper respiratory tract infection.

4 at resulted in two bacteremias and one lower respiratory tract infection.

5 ere pulmonary exacerbation, cough, and upper respiratory tract infection.

6 amyxovirus that causes acute upper and lower respiratory tract infection.

7 as reduction in the incidence of viral upper respiratory tract infection.

8 l aspirate from a 7-month-old patient with a respiratory tract infection.

9 vg+) phase that are necessary for successful respiratory tract infection.

10 on following a primary diagnosis of an upper respiratory tract infection.

11 rs), 414 (47%) were women, and 379 (43%) had respiratory tract infection.

12 a exacerbations, and hospital attendance for respiratory tract infections.

13 sitive and culture-negative sepsis and lower respiratory tract infections.

14 f future hospital admission in children with respiratory tract infections.

15 appropriate antibiotic prescribing for acute respiratory tract infections.

16 articular concern in the management of lower respiratory tract infections.

17 the appropriate use of antibiotics for acute respiratory tract infections.

18 rum antibiotics for most children with acute respiratory tract infections.

19 before and after controlling for early-life respiratory tract infections.

20 t SSIs, susceptible staphylococcal SSIs, and respiratory tract infections.

21 ention of medically attended RSV acute lower respiratory tract infections.

22 enterococcal SSIs, but increase the risk of respiratory tract infections.

23 endations for targets in children with lower respiratory tract infections.

24 n children for the prevention of viral upper respiratory tract infections.

25 rging viral, bacterial, and fungal causes of respiratory tract infections.

26 AQLQ(S)], and incidence of exacerbations and respiratory tract infections.

27 2Rs may have therapeutic potential for upper respiratory tract infections.

28 R-deficient patients suffered from recurrent respiratory tract infections.

29 mune diseases, hematologic malignancies, and respiratory tract infections.

30 nts and young children to severe viral lower respiratory tract infections.

31 escribing of antibiotics for childhood upper respiratory tract infections.

32 ae (NTHI) is the causative agent of multiple respiratory tract infections.

33 tion did not reduce overall wintertime upper respiratory tract infections.

34 ospitalized patients <2 years old with lower respiratory tract infections.

35 gic association in persons with severe lower respiratory tract infections.

36 in D levels and a higher risk of viral upper respiratory tract infections.

37 ide and represent the leading cause of upper respiratory tract infections.

38 e been developed to monitor the emergence of respiratory-tract infections.

39 itudinal models [95% CI]: 0.71 [0.54-0.94]), respiratory tract infections (0.77 [0.59-0.99]), otitis

40 ent (PAD) patients, 4 (5%) adults with lower respiratory tract infection, 1 (2.6%) sputum sample from

41 a (13 [12%]), headache (11 [10%]), and upper respiratory tract infection (11 [10%]).

42 ine [43%] patients receiving placebo), upper respiratory tract infection (11 [25%] patients vs two [1

43 ction (19 [7%] vs 11 [4%] vs 13 [5%]), upper respiratory tract infection (15 [5%] vs 15 [5%] vs 11 [4

44 on (343 [45%] infections), followed by lower respiratory tract infections (171 [22%]), gastrointestin

45 21 [20%] of 107 vs seven [6%] of 110), upper respiratory tract infections (18 [17%] vs ten [9%]), and

46 two studies, 1 681 020 events) and for lower respiratory tract infections (-18.48% [-32.79 to -4.17];

47 or abnormal dreams (4 [10%] vs none), upper respiratory tract infection (3 [7%] vs none], and urinar

48 s), and rates of hospital attendance for all respiratory tract infections (-3.45% [-4.64 to -2.25]; t

49 67 [29%] for reslizumab for study 2), upper respiratory tract infections (32 [13%] and 39 [16%]; 16

50 h dupilumab compared with placebo were upper respiratory tract infections (33-41% vs 35%) and injecti

51 haryngitis (30 [11%] vs 15 [11%]), and upper respiratory tract infection (35 [12%] vs ten [7%]).

52 ost common adverse events overall were upper respiratory tract infection (51 [9%] of 581 patients rec

53 tients), rhinitis (10 [16%] patients), upper respiratory tract infection (7 [11%] patients), and coug

54 ts were fatigue (25%), headache (13%), upper respiratory tract infection (8%), and arthralgia (8%).

55 Acute respiratory tract infections account for the majority of

56 cessful treatment outcomes for patients with respiratory tract infections across all health-care sett

57 c-inappropriate diagnoses (nonspecific upper respiratory tract infections, acute bronchitis, and infl

58 t hospitalizations for all-cause acute lower respiratory tract infection (ALRI).

59 among patients hospitalized with acute lower respiratory tract infections (ALRTIs).

60 dged reasonably related to siltuximab (lower respiratory tract infection, anaphylactic reaction, seps

61 d high risk of future hospital admission for respiratory tract infection and could be used to reduce

62 from patients hospitalized with acute lower respiratory tract infection and identified factors assoc

63 y elective CS had an increased risk of lower respiratory tract infection and juvenile idiopathic arth

64 patients with community-acquired mild lower respiratory tract infection and matched controls of Cauc

65 months and 12 years diagnosed with an acute respiratory tract infection and prescribed an oral antib

66 nly reported adverse events (AEs) were upper respiratory tract infection and stomatitis of mostly gra

67 isable, causal association between RSV lower respiratory tract infection and subsequent long-term whe

68 ncytial virus (RSV) is responsible for lower respiratory tract infections and annually results in 200

69 three common viruses implicated in seasonal respiratory tract infections and are a major cause of mo

70 s, are responsible for the majority of upper respiratory tract infections and are associated with sev

71 general nontuberculosis morbidity, including respiratory tract infections and atopic diseases.

72 tions, events that are often associated with respiratory tract infections and cold symptoms.

73 or dysfunction, anxiety, epilepsy, recurrent respiratory tract infections and early death.

74 Bacterial respiratory tract infections and exacerbations of chroni

75 esent in the nasal mucosa during acute viral respiratory tract infections and further characterize th

76 us (RSV) is the leading cause of acute lower respiratory tract infections and hospitalizations in inf

77 Haemophilus influenzae (Hi) causes respiratory tract infections and is also considered to b

78 ory syncytial virus (RSV) causes acute lower respiratory tract infections and is the leading cause of

79 teroid-insensitive asthma is associated with respiratory tract infections and noneosinophilic endotyp

80 , influenza, and respiratory syncytial virus respiratory tract infections and ovalbumin-induced, seve

81 The sister had recurrent respiratory tract infections and severe skin disease, wh

82 The main features include respiratory tract infections and their associated compli

83 tackle emerging viruses that can cause fatal respiratory tract infections and to fill major gaps in t

84 ietary supplements, primarily to treat upper respiratory tract infections and to support immune funct

85 The incidence density ratios of total respiratory-tract infections and gastrointestinal-tract

86 n adverse events were nausea, anaemia, upper respiratory tract infection, and headache.

87 verse events were injection-site pain, upper respiratory tract infection, and nausea.

88 %]), febrile neutropenia (five [10%]), lower respiratory tract infection, and pneumonia (each three [

89 iratory tract illnesses, time to first upper respiratory tract infection, and serum 25-hydroxyvitamin

90 d placebo groups were dyspnoea, cough, upper respiratory tract infection, and worsening of IPF; and t

91 nd susceptibility to allergic sensitization, respiratory tract infections, and asthma.

92 r respiratory tract infections, severe lower respiratory tract infections, and exacerbations of under

93 isodes of troublesome lung symptoms, asthma, respiratory tract infections, and neonatal airway immuno

94 Infusion-related reactions, upper respiratory tract infections, and oral herpes infections

95 y symptoms, severity of gastrointestinal and respiratory tract infections, and the use of antibiotics

96 Respiratory tract infections are an important cause of m

97 Viral respiratory tract infections are associated with asthma

98 Respiratory tract infections are caused by many differen

99 Respiratory tract infections are frequent causes of hosp

100 Respiratory tract infections are one of the leading caus

101 Viral respiratory tract infections are the main causative agen

102 Viral respiratory tract infections are the most common human a

103 y-confirmed antibiotic-resistant urinary and respiratory-tract infections are more likely to experien

104 elines on antibiotic prescriptions for acute respiratory tract infection (ARTI) in PEDs.

105 Acute respiratory tract infection (ARTI) is the most common re

106 didates were efficacious in preventing lower respiratory tract infection as well as in reducing the n

107 tis media development, but symptomatic upper respiratory tract infection (as opposed to asymptomatic

108 used Bordetella pertussis, a common neonatal respiratory tract infection, as a proof of concept to in

109 Asthma-, allergy-, and respiratory tract infection-associated phenotypes (inclu

110 and the secondary end points included lower respiratory tract infections, asthma exacerbations, ecze

111 Controlling for respiratory tract infections attenuated estimates for ac

112 riate antibiotic prescribing for acute upper respiratory tract infections (AURIs) requires a better u

113 e number of laboratory-confirmed viral upper respiratory tract infections based on parent-collected n

114 ce of common nosocomial gastrointestinal and respiratory tract infections between groups (22 vs. 29 i

115 en hospitalized at one institution for lower respiratory tract infections between January 1, 2010, an

116 Among children with acute respiratory tract infections, broad-spectrum antibiotics

117 n are often triggered by viral and bacterial respiratory tract infections, but there is little eviden

118 nterval, 0.16-0.80; P = 0.01), but increased respiratory tract infections by 54% (relative risk, 1.54

119 Lower respiratory tract infections by respiratory syncytial vi

120 uman respiratory syncytial virus (RSV) lower respiratory tract infection can result in inflammation a

121 While most viral respiratory tract infections can be diagnosed clinically

122 Lower respiratory tract infections caused by bacteria are a ma

123 rise in the global numbers of patients with respiratory tract infections caused by pan-antibiotic-re

124 ied a child with life-threatening, recurrent respiratory tract infections, caused by viruses includin

125 , stinging insects, fungi, pollutants, viral respiratory tract infections, climate change, and microb

126 60 yr) patients in health and during a lower respiratory tract infection, community-acquired pneumoni

127 The most frequent AEs were fatigue, upper respiratory tract infection, cough, and dyspnea.

128 hope in revolutionising rapid point of care respiratory tract infection diagnostics.

129 peripheral edema, skin ulcer, anemia, upper respiratory tract infection, diarrhea, and nasopharyngit

130 ice with TP73 deficiency suffer from chronic respiratory tract infections due to profound defects in

131 al virus (RSV) is the primary cause of lower respiratory tract infection during childhood and causes

132 have highlighted the important role of viral respiratory tract infections during infancy and early ch

133 9% women) for antibiotic-inappropriate acute respiratory tract infections during the baseline period

134 ation study and subsequent symptoms of lower respiratory tract infections during the first year of li

135 a human pathogen that can cause severe lower respiratory tract infections, especially in infants.

136 HBoV1 is pathogenic to humans, causing acute respiratory tract infections, especially in young childr

137 llenges in improving management outcomes for respiratory tract infections exist: rapid identification

138 lated from nasal lavage fluid during a viral respiratory tract infection expressed CysLTR1.

139 eight [8%] patients in each group) and upper respiratory tract infections (five [5%] patients in each

140 6, the most common adverse events were upper respiratory tract infections (four [4%], eight [8%], ten

141 Lower respiratory tract infections from respiratory syncytial

142 Adverse events were manageable and included respiratory tract infections, gastrointestinal symptoms,

143 k before the onset of symptoms, a mild upper respiratory tract infection had developed.

144 ects of oral corticosteroids for acute lower respiratory tract infection in adults without asthma.

145 ruses (RVs) are a major cause of symptomatic respiratory tract infection in all age groups.

146 tial virus (RSV) is the major cause of lower respiratory tract infection in children worldwide.

147 ocavirus (HBoV) 1 can cause life-threatening respiratory tract infection in children.

148 re present during symptoms of an acute viral respiratory tract infection in human subjects.

149 (RSV) is the most significant cause of lower respiratory tract infection in infancy worldwide.

150 RSV and hMPV are the leading causes of acute respiratory tract infection in infants and children.

151 RSV and hMPV are the leading causes of acute respiratory tract infection in infants and children.

152 the most prevalent worldwide cause of severe respiratory tract infection in infants and young childre

153 nza virus type 3, two major causes of severe respiratory tract infection in infants and young childre

154 syncytial virus (RSV) is a leading cause of respiratory tract infection in infants, causing signific

155 rus (hRSV) is a leading cause of acute lower respiratory tract infection in infants, elderly and immu

156 ute bronchiolitis is the most frequent lower respiratory tract infection in infants, yet there are no

157 us (RSV) is the most frequent cause of lower respiratory tract infection in infants.

158 e coronavirus (MERS-CoV) causes severe lower respiratory tract infection in people.

159 efficiently inhibits established acute lower respiratory tract infection in the animals, even when tr

160 the pitavastatin group (n=12, 10%) and upper respiratory tract infection in the pravastatin group (n=

161 tial virus (RSV) is a leading cause of lower respiratory tract infection in young children worldwide.

162 cytial virus is a major cause of acute lower respiratory tract infection in young children, immunocom

163 -level proportion of prescriptions for upper respiratory tract infections in 2-14-year-old outpatient

164 cause of otitis media in children and lower respiratory tract infections in adults with chronic obst

165 fluenzae frequently causes noninvasive upper respiratory tract infections in children but can also ca

166 e (NTHi) frequently causes noninvasive upper respiratory tract infections in children but can cause i

167 us (RSV) is a major cause of upper and lower respiratory tract infections in children for which no va

168 RSV) is the leading etiologic agent of lower respiratory tract infections in children, but no license

169 (hRSV) is the leading cause of severe lower respiratory tract infections in children.

170 an metapneumovirus (HMPV), a common cause of respiratory tract infections in children.

171 irus (RSV) is a leading cause of acute lower respiratory tract infections in children.

172 tial virus (RSV) is a leading cause of lower respiratory tract infections in children.

173 rrow-spectrum antibiotic treatment for acute respiratory tract infections in children.

174 (HPIVs) are among the most common causes of respiratory tract infections in children.

175 The results provide new evidence that respiratory tract infections in early life predict the d

176 Adjustment for respiratory tract infections in early life substantially

177 eptibility and exaggerated response to lower respiratory tract infections in general rather than on t

178 mergence of several novel viruses that cause respiratory tract infections in human beings, including

179 cause the majority of acute upper and lower respiratory tract infections in humans, particularly in

180 ly in the Paramyxoviridae family that causes respiratory tract infections in humans.

181 served in vivo and the occurrence of chronic respiratory tract infections in immunocompromised hosts.

182 erum and causes otitis media in children and respiratory tract infections in individuals with underly

183 he most common viruses associated with acute respiratory tract infections in infancy.

184 al virus (RSV) is the leading cause of lower respiratory tract infections in infant and elderly popul

185 RSV) is the most common cause of viral lower respiratory tract infections in infants and children und

186 hRSV is a leading cause of lower respiratory tract infections in infants and young childr

187 al virus (RSV) is the leading cause of lower respiratory tract infections in infants, a safe and effe

188 genome viruses, is a leading cause of lower respiratory tract infections in infants, young children,

189 tial virus (RSV) can cause devastating lower respiratory tract infections in preterm infants or when

190 sis of HIES plus hypereosinophilia and upper respiratory tract infections in the absence of parenchym

191 Lower respiratory tract infections in the first years of life

192 ed with an increased risk of upper and lower respiratory tract infections in the outpatient setting b

193 al virus (RSV) is the leading cause of lower respiratory tract infections in the very young.

194 biotic use in patients with non-severe acute respiratory tract infections in Vietnam.

195 RSV is a major cause of serious lower respiratory tract infections in young children and cause

196 HBoV1 causes acute respiratory tract infections in young children and has a

197 le-stranded DNA parvovirus that causes lower respiratory tract infections in young children worldwide

198 emerging respiratory virus that causes lower respiratory tract infections in young children worldwide

199 single most important cause of serious lower respiratory tract infections in young children, yet no h

200 single most important cause of serious lower respiratory tract infections in young children, yet no h

201 Human bocavirus 1 (HBoV1) causes acute respiratory tract infections in young children.

202 BoV1) is pathogenic to humans, causing acute respiratory tract infections in young children.

203 on reduces the incidence of wintertime upper respiratory tract infections in young children.

204 1 (HBoV1), a human parvovirus, causes lower respiratory tract infections in young children.

205 oV1) is a human parvovirus that causes acute respiratory tract infections in young children.

206 ytial virus (RSV) is the main cause of lower respiratory tract infections in young children.

207 a major causative agent of upper- and lower-respiratory-tract infections in infants, the elderly, an

208 ild diarrhea (in 52% of the patients), upper respiratory tract infection (in 48%), nausea (in 47%), a

209 Common grade 1-2 toxicities included upper respiratory tract infections (in 28 [57%] of 49 patients

210 Multiplex tests for respiratory tract infections include up to 20 targets fo

211 Viral respiratory tract infections increase the risk of develo

212 CD4 cell counts are at higher risk for lower respiratory tract infections, indicating impaired local

213 thelial secretome participating in RSV lower respiratory tract infection-induced airway remodeling.

214 n adverse events were nasopharyngitis, upper respiratory tract infection, influenza, and back pain.

215 s pneumoniae, the transition to severe lower respiratory tract infection is associated with an increa

216 Acute lower respiratory tract infection is common and often treated

217 Respiratory syncytial virus (RSV) lower respiratory tract infection is implicated in asthma deve

218 utrophils are recruited to the site of viral respiratory tract infection is not clear.

219 g for viruses in children who present with a respiratory tract infection is to differentiate between

220 Inappropriate antibiotic use for acute respiratory tract infections is common in primary health

221 ad-spectrum antibiotic prescribing for acute respiratory tract infections is increasing.

222 nfancy, specifically the occurrence of lower respiratory tract infection, is associated with low lung

223 can predict the risk of progression to lower respiratory tract infection (LRTI) and RSV-associated mo

224 here is no effective treatment for RSV lower respiratory tract infection (LRTI) and that supportive c

225 Lower respiratory tract infection (LRTI) commonly causes hospi

226 inguishing between bacterial and viral lower respiratory tract infection (LRTI) remains challenging.

227 ed pneumonia, and secondary outcome, a lower respiratory tract infection (LRTI) without radiographic

228 iratory tract infection (URTI) without lower respiratory tract infection (LRTI), URTI progressing to

229 5.84 (95% CI 5.61-6.08; p < 0.001) for lower respiratory tract infection (LRTI).

230 common reason for hospitalization was lower respiratory tract infection (LRTI).

231 nificance remains unclear in pediatric lower respiratory tract infection (LRTI).

232 Lower respiratory tract infections (LRTIs) are a persistent an

233 cytial virus (RSV) and rhinovirus (RV) lower respiratory tract infections (LRTIs) being strongly asso

234 spiratory tract infections (URTIs) and lower respiratory tract infections (LRTIs) was collected with

235 l pathogen in hospitalized adults with lower respiratory tract infections (LRTIs).

236 growth of pathogens potentially relevant to respiratory tract infection may be triggered by changes

237 ncreased dissemination to blood in the lower respiratory tract infection model.

238 ich underlie the increased susceptibility to respiratory tract infections of patients with Down syndr

239 3 infections (two lung infections, one upper respiratory tract infection, one sepsis, and one mucosit

240 y their child exhibited symptoms of an upper respiratory tract infection or asthma exacerbation (epis

241 Eighteen (86%) patients were treated for respiratory tract infections; others were treated for bl

242 es of cow's milk and occurrence of rhinitis, respiratory tract infections, otitis, and fever were ass

243 irus (CMV) antigenemia (p = 0.005) and lower respiratory tract infection (p = 0.003) and no leucopeni

244 ly associated with a recent history of upper respiratory tract infections (P = 0.0064), and marked by

245 he mean number of laboratory-confirmed upper respiratory tract infections per child was 1.05 (95% CI,

246 Subject Headings terms: "acute bronchitis," "respiratory tract infection," "pharyngitis," "rhinosinus

247 The most frequent adverse events were upper respiratory tract infection (placebo 6 [7%] patients vs

248 considering prevention or treatment of viral respiratory tract infections, potential targets include

249 ypically young children with upper and lower respiratory tract infection, presenting with symptoms in

250 icantly worse survival than those with upper respiratory tract infection (probable: hazard ratio [HR]

251 Respiratory tract infections rank second as causes of ad

252 elop respiratory syncytial virus acute lower respiratory tract infection.Respiratory syncytial virus

253 Respiratory tract infections (RTI) frequently cause hosp

254 fluenzae is a significant causative agent of respiratory tract infections (RTI) worldwide.

255 safe strategies for the prevention of viral respiratory tract infections (RTIs) are needed.

256 Handwashing to prevent transmission of respiratory tract infections (RTIs) has been widely advo

257 urden of severe human metapneumovirus (HMPV) respiratory tract infections (RTIs) in European children

258 ota stability and thereby resistance against respiratory tract infections (RTIs) over time.

259 fection rates, and identify risk factors for respiratory tract infections (RTIs).

260 outcomes (incidence of gastrointestinal and respiratory tract infections separately, duration of gas

261 ized adults varies widely and includes upper respiratory tract infections, severe lower respiratory t

262 Respiratory tract infections should be accounted for in

263 healthy individuals with a history of upper respiratory tract infection, soft tissue contusion, and

264 efit of ribavirin-based therapy at the upper respiratory tract infection stage and the highest risk f

265 hat colonize the human pharynx and can cause respiratory tract infections, such as acute otitis media

266 osteroids should not be used for acute lower respiratory tract infection symptoms in adults without a

267 or duration or severity of other acute lower respiratory tract infection symptoms, duration of abnorm

268 es were duration and severity of acute lower respiratory tract infection symptoms, duration of abnorm

269 Atopy and viral respiratory tract infections synergistically promote ast

270 vents in both groups were headache and upper respiratory tract infection (ten [16%] for both events i

271 act animals demonstrated various symptoms of respiratory tract infection, they were mild, and the cal

272 ral, bacterial, or fungal pathogens, such as respiratory tract infections, this necessitates large pa

273 ght increase the risk of asthma symptoms and respiratory tract infections throughout childhood.

274 an increased risk of progression from upper respiratory tract infection (URI) to LRD.

275 Such common diagnoses as upper respiratory tract infection, urinary tract infection, an

276 al (months 1-6 and month 9) and during upper respiratory tract infection (URTI) episodes.

277 s completed daily from the onset of an upper respiratory tract infection (URTI) until asthma symptom

278 e grouped according to the presence of upper respiratory tract infection (URTI) without lower respira

279 Information on upper respiratory tract infections (URTIs) and lower respirato

280 We assessed the seasonality of viral lower respiratory tract infections (V-LRI), bacteremic pneumon

281 LRE1C in three index patients with recurrent respiratory tract infections, very low B-cell numbers an

282 One treatment-related death from a respiratory tract infection was reported in the docetaxe

283 sLTR1 signaling in the first days of a viral respiratory tract infection was sufficient to reduce acc

284 The increasingly recognized role of viral respiratory tract infections was reflected in publicatio

285 one focal and one systemic symptom of acute respiratory tract infection were assigned 1:1 to receive

286 Patients with severe acute respiratory tract infection were excluded.

287 enting with acute cough (for </=28 days) and respiratory tract infection were recruited to a prognost

288 of in-county children hospitalized for lower respiratory tract infections were admitted to Cincinnati

289 Respiratory tract infections were most common and were d

290 ous events (SIEs) (gastroenteritis and lower respiratory tract infections) were investigated for 751

291 piratory syncytial virus (RSV) causes severe respiratory tract infections, which might have a role in

292 pansion of CD8(+) T cells following an upper respiratory tract infection with a pathogenic influenza

293 dex was found to be a robust marker of viral respiratory tract infection with a sensitivity of 80% an

294 New viral respiratory tract infections with epidemic potential, su

295 Although preceding respiratory tract infections with Mycoplasma pneumoniae

296 infections (comprising both upper and lower respiratory tract infections with viruses, bacteria, and

297 eumovirus (HMPV) is a leading cause of acute respiratory tract infection, with significant morbidity

298 The outcome was hospital admission for respiratory tract infection within 30 days, collected us

299 reduced antibiotic use for non-severe acute respiratory tract infection without compromising patient

300 Human metapneumovirus is a major cause of respiratory tract infections worldwide.